APA (7th ed.) Citation

E, M. R., Y, H., S, Y., V, T., S, B., P, v. H., . . . L, C. (2024). Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments. Journal of central nervous system disease, 16, 11795735241260563. https://doi.org/10.1177/11795735241260563

Chicago Style (17th ed.) Citation

E, Muros-Le Rouzic, et al. "Five-year Efficacy Outcomes of Ocrelizumab in Relapsing Multiple Sclerosis: A Propensity-matched Comparison of the OPERA Studies with Other Disease-modifying Therapies in Real-world Lines of Treatments." Journal of Central Nervous System Disease 16 (2024): 11795735241260563. https://doi.org/10.1177/11795735241260563.

MLA (9th ed.) Citation

E, Muros-Le Rouzic, et al. "Five-year Efficacy Outcomes of Ocrelizumab in Relapsing Multiple Sclerosis: A Propensity-matched Comparison of the OPERA Studies with Other Disease-modifying Therapies in Real-world Lines of Treatments." Journal of Central Nervous System Disease, vol. 16, 2024, p. 11795735241260563, https://doi.org/10.1177/11795735241260563.